This is an Ipsen Biopharmaceuticals Inc. sponsored Product Theatre and is intended for healthcare professionals only. This video is disease-specific with no discussion about treatments.
An Ipsen meeting during The Liver Meeting by the American Association for the Study of Liver Disease (AASLD) 2023, Boston, Massachusetts, USA.
In order to make meaningful improvements to the lives of people living with primary biliary cholangitis (PBC), it is important to look beyond the liver. Adaptive and personalised patient care is key to achieve optimal outcomes for people living with PBC, and must take into consideration the needs of patients with substantial risk of disease progression and/or symptomatic disease.
This approach includes:
1. Evaluation of individual patient risk profiles.
2. Timely follow-up and assessment of biochemical response.
3. Consideration and mitigation of the impact of symptoms on patients’ quality of life
At AASLD 2023, David Jones (UK) and Marlyn Mayo (USA) provided their insights around this topic, and highlighted the remaining unmet needs for people living with PBC and approaches to address them.
ELA-ALL-000923, ELA-US-000256, ELA-UK-000025
April 2024
